# Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer

> **NCT06980545** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Assiut University** · enrollment: 50 (estimated)

## Conditions studied

- Stage III and IV Ovarian Cancer

## Interventions

- **DRUG:** Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)

## Key facts

- **NCT ID:** NCT06980545
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2026-04-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06980545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06980545, "Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06980545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*